Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-19), Cabio Biotech (Wuhan) Co's Beta is 1.4282.
Cabio Biotech (Wuhan) Co (SHSE:688089) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabio Biotech (Wuhan) Co Beta vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's Beta distribution charts can be found below:
* The bar in red indicates where Cabio Biotech (Wuhan) Co's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Cabio Biotech (Wuhan) Co (SHSE:688089) has a Beta of 1.4282 as of Jul. 19, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cabio Biotech (Wuhan) Co and its competitors.
Is Cabio Biotech (Wuhan) Co's Beta too high?
Cabio Biotech (Wuhan) Co's current Beta is 1.4282. Overall, Cabio Biotech (Wuhan) Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cabio Biotech (Wuhan) Co's Beta compare to VRTX and REGN?
Cabio Biotech (Wuhan) Co's Beta of 1.4282 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cabio Biotech (Wuhan) Co and its competitors. Cabio Biotech (Wuhan) Co's current Beta is 1.4282. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabio Biotech (Wuhan) Co stock overvalued right now?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co (SHSE:688089) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.66, compared to a current price of ¥10.61 — trading 48.6% below its estimated fair value. The current Beta is 1.4282. Cabio Biotech (Wuhan) Co's overall GF Score™ is 67/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cabio Biotech (Wuhan) Co (SHSE:688089), the current Beta is 1.4282 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cabio Biotech (Wuhan) Co (SHSE:688089) Overvalued in 2026?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co stock appears to be undervalued.
The current stock price of ¥10.61 is trading 48.6% below its estimated GF Value™ of ¥20.66.
GuruFocus considers Cabio Biotech (Wuhan) Co to be Possible Value Trap.
Key valuation signals for SHSE:688089:
Beta: 1.4282
GF Value™: ¥20.66 vs. price of ¥10.61 (48.6% below fair value)
No single metric tells the full story. See the SHSE:688089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
67GF Score
Get the complete analysis for SHSE:688089
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688089 has been successfully added to your 
